This article first appeared on GuruFocus .
Release Date: August 13, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Dare Bioscience Inc ( NASDAQ:DARE ) launched its first directly commercialized product, FloraSync LF5, in June 2026, marking a significant milestone in its transition to a commercial-stage company.
-
The company's second product, Dare to Play Sildenafil Cream, is approaching prescription dispensing, with early indicators showing a healthy mix of prescriptions from office providers and telehealth, as well as repeat prescriptions.
-
Dare Bioscience Inc ( NASDAQ:DARE ) is advancing its pipeline with positive interim results for Ovaprine, and the FDA approved a protocol amendment that could accelerate its path to a top-line data announcement in 2027.
-
The company secured additional non-dilutive funding, including a second $1 million award from NIAID, bringing total funding for its HPV program to $2 million and reducing its R&D expenses.
-
Dare Bioscience Inc ( NASDAQ:DARE ) is building a scalable commercial platform with the Dare Health Hub, which is designed to support multiple product launches and create a diversified multi-product revenue profile by 2027.
-
The company's net loss improved to approximately $3 million in Q2 2026, compared to a $4 million loss in the prior-year period, reflecting disciplined capital allocation.
Negative Points
-
Dare Bioscience Inc ( NASDAQ:DARE ) reported a working capital deficit of approximately $0.2 million as of June 30, 2026, indicating potential liquidity concerns.
-
The company's Q2 2026 revenue was minimal at approximately $0.2 million, and it did not include any sales from FloraSync LF5, which only began in July, highlighting the early stage of commercial revenue generation.
-
Dare to Play Sildenafil Cream is not yet dispensing, and the company faces uncertainty regarding the timing and success of its launch, despite receiving early prescriptions.
-
The FDA, while approving the protocol amendment for Ovaprine, continued to strongly recommend a minimum of 250 completers, suggesting potential regulatory hurdles or disagreements that could impact the study's acceptability.
-
The company's SG&A expenses increased to $2.6 million in Q2 2026, driven by a non-cash write-down of deferred offering costs and investments in commercial readiness, which could pressure future cash flows.
-
Dare Bioscience Inc ( NASDAQ:DARE ) has a limited cash position of $12.6 million, which may not be sufficient to fund all its planned commercial and clinical activities without additional financing.
Q & A Highlights
Q: Can you share your thoughts on the near-term commercial portfolio, specifically how you plan to pull together FloraSync LF5, Dare to Play, and Dare to Reclaim, given their different end-user profiles and promotional needs? Do you anticipate building a DARE brand, or will these products stand on their own? A: Sabrina Martucci-Johnson, President and CEO, explained that while the products are distincta non-prescription probiotic, a prescription arousal cream, and a menopause hormone therapy ringthey all share a foundation of credible clinical evidence. She emphasized that the DARE brand is crucial, as the company is the only biotech working broadly and solely across women's health therapeutics. The strategy leverages the DARE Health Hub as a central commercial platform to reach women actively seeking solutions, with a healthy mix of prescriptions coming from both office providers and telehealth channels, validating the approach.
Q: Do you think the DARE brand will resonate more with clinicians or with patients? A: Sabrina Martucci-Johnson, President and CEO, stated that the brand is designed to resonate with both. The company has established relationships across the women's health community, which it uses to educate providers, who in turn educate each other and serve as trusted sources for women. Simultaneously, DARE is building its brand directly with consumers through influencer providers and trusted online sources of information.
Q: Regarding Dare to Reclaim, how do you think about converting women from often compounded or oral products to this new intravaginal ring, especially given the recent regulatory tailwinds around hormone replacement therapy? A: Sabrina Martucci-Johnson, President and CEO, expressed excitement about the product, targeting market availability in 2027. She noted that clinicians are eagerly awaiting it due to the shortage of patches and the cumbersome nature of current combination therapies. The product's clinical evidence, demonstrating the necessary pharmacokinetic levels of estradiol and progesterone in a non-oral form, aligns with Menopause Society recommendations, making it a product that will do the heavy lifting in converting patients due to its convenience and clear clinical backing.
Q: What are the key financial results for the second quarter of 2026? A: Marty Herring Layton, Chief Accounting Officer, reported that the company ended the quarter with approximately $12.6 million in cash and cash equivalents. Total revenue for Q2 2026 was approximately $0.2 million, consisting solely of R&D services and royalty revenue, as FloraSync LF5 sales began in July. SG&A expenses increased to $2.6 million, while R&D expenses decreased significantly to $0.2 million due to non-dilutive funding offsets. The net loss improved to approximately $3 million, compared to a $4 million loss in the prior-year period.
Q: Can you provide an update on the Ovaprine Phase 3 study and the recent FDA protocol amendment? A: Sabrina Martucci-Johnson, President and CEO, stated that the pivotal Phase 3 study continues to advance, with positive interim results and a DSMB recommendation to continue without modification. In August 2026, the FDA approved a protocol amendment to remove the expectation of 250 completers. While the FDA strongly recommends this target, the company believes the study's expected achievement of at least 2,500 menstrual cycles of exposure will generate sufficient safety data to support a PMA submission. Top-line data is expected in 2027.
Q: What is the commercial strategy for the newly launched FloraSync LF5 and the upcoming Dare to Play sildenafil cream? A: Sabrina Martucci-Johnson, President and CEO, outlined a strategy that begins with providers (OB/GYNs) as trusted voices, expands through digital marketing to educate women, and leverages telehealth for national reach. The DARE Health Hub serves as the central destination for education, product access, and fulfillment. The company is focused on three key performance indicators: consumer adoption, provider adoption, and commercial efficiency, to evaluate the early launch period and guide scaling efforts.
Q: What is the market opportunity for Dare to Play sildenafil cream, and what is the rationale behind the dual-path regulatory strategy? A: Sabrina Martucci-Johnson, President and CEO, highlighted that an estimated 20 million women in the U.S. experience symptoms of low or no sexual arousal, representing a total market opportunity of approximately $2 billion at a price of $99 per tube. The dual-path strategy involves commercializing via the 503B compounding pathway for capital-efficient early market entry while pursuing FDA approval through the 505 pathway. FDA approval would provide greater confidence among patients and prescribers, enable payer coverage, and potentially make it the first FDA-approved treatment for female sexual arousal disorder.
Q: Can you provide an update on the HPV program and its funding? A: Sabrina Martucci-Johnson, President and CEO, announced the initiation of a Phase 2 study for their HPV program, expected to enroll approximately 100 women with persistent high-risk HPV infection, with top-line results expected in 2027. The study is supported by a contract funded by ARPA-H. Additionally, the company received a funding award notice for a second $1 million project from NIAID, bringing the total funding for the project period to $2 million.
Q: What is the timeline for Dare to Reclaim estradiol progesterone intravaginal ring, and what is its potential? A: Sabrina Martucci-Johnson, President and CEO, stated that activities to support commercial availability through the 503B compounding pathway are underway, with dispensing targeted to begin in 2027. The product addresses a significant unmet need in menopause hormone therapy, and the company believes its clinical evidence and convenience will drive adoption, especially given the current shortage of patches and the cumbersome nature of existing combination therapies.
Q: How is the company evaluating performance during the early launch period, and what are the objectives for 2026? A: Sabrina Martucci-Johnson, President and CEO, explained that the company is focused on three primary groups of commercial indicators: consumer adoption (conversion and recurring demand), provider adoption (consistent prescribing and stocking), and commercial efficiency (channel performance and spending effectiveness). For 2026, the objective is disciplined execution and commercial validation, establishing the benchmarks and repeatable processes needed to support stronger and more efficient growth in 2027 and beyond.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
